PT-141, also known as Bremelanotide, is a synthetic peptide melanocortin receptor agonist.
It is the first FDA-approved peptide that enhances sexual desire through the brain’s arousal pathways instead of the vascular system. In 2019, it was approved under the name Vyleesi® for women with hypoactive sexual desire disorder (HSDD), making it a groundbreaking therapy for low libido.
It also does wonders for Men too and is totally different to Viagra or Cialis since it bypasses nitric oxide pathways.
For Women
→ FDA-approved treatment for HSDD: Clinical studies demonstrated that PT-141 significantly increased sexual desire scores in women diagnosed with hypoactive sexual desire disorder.
→ Improved satisfaction: Women reported higher levels of sexual fulfillment and responsiveness, not just increased frequency of activity.
→ Neurobiological effect: By acting on the brain, PT-141 helps restore the psychological component of arousal, which PDE-5 inhibitors cannot address.
For Men
→ Alternative for ED non-responders: Men who fail to respond to Viagra or Cialis often benefit from PT-141 since it bypasses nitric oxide pathways.
→ Enhanced erectile response: Studies suggest improvements in both erection quality and sexual desire, making it effective for organic and psychogenic ED.
→ Boosts sexual motivation: Some men report heightened mental arousal and confidence, not just physical readiness.
Lifestyle & Performance Applications
→ Off-label use: Beyond clinical therapy, PT-141 is used in performance and wellness communities for its ability to increase libido and intimacy.
→ Synergy with lifestyle: Users often describe improved connection with partners, heightened mood, and overall quality of sexual experiences.
→ Psychological boost: Unlike purely physical aids, PT-141 may reduce anxiety around intimacy, contributing to better performance and satisfaction.
Supplied for in vitro research purposes. High-purity lyophilised compound with certificate of analysis.